GlassScriptPhysician profile
Pranitha Vbr Prodduturvar
NPI 1114183902
$33,392.00
in general payments reported to CMS, 2019-2025
57 companies · $1,037 in 2025
The $1,037 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $117 · 2021: $115 · 2022: $3,502 · 2023: $13K · 2024: $16K · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $5,709 · Consulting Fee: $4,500 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,835.00 |
| Food and Beverage | $5,709.02 |
| Consulting Fee | $4,500.00 |
| Education | $315.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23,942.55 | 2022-2024 | Opdivo |
| Genzyme Corporation | $1,472.19 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $663.74 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Janssen Biotech, INC. | $613.23 | 2022-2025 | Erleada, Akeega, Tecvayli |
| Novartis Pharmaceuticals Corporation | $608.12 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $606.62 | 2022-2024 | Libtayo |
| Eisai INC. | $564.74 | 2019-2024 | |
| Incyte Corporation | $501.96 | 2020-2025 | Monjuvi, Pemazyre, Jakafi |
| Amgen INC. | $479.59 | 2019-2023 | Kyprolis |
| Merck Sharp & Dohme LLC | $428.76 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $421.49 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $388.41 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $305.76 | 2020-2025 | Iclusig, Alunbrig, Ninlaro |
| Genentech USA, INC. | $225.65 | 2022-2025 | Tecentriq, Phesgo, Lunsumio |
| Pfizer INC. | $211.21 | 2020-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $164.86 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Seagen INC. | $155.06 | 2021-2025 | Padcev, Tivdak |
| Dendreon Pharmaceuticals LLC | $104.54 | 2022-2025 | Provenge |
| Abbvie INC. | $103.96 | 2023-2025 | |
| Pharmaessentia USA Corporation | $93.35 | 2023-2024 | Besremi |
| Lilly USA, LLC | $82.24 | 2020-2025 | Verzenio, Retevmo, Jaypirca |
| Beigene USA, INC. | $81.34 | 2022-2024 | Brukinsa |
| Gilead Sciences, INC. | $74.80 | 2022-2023 | Trodelvy |
| Stemline Therapeutics INC. | $73.69 | 2023-2025 | Orserdu |
| Sobi, INC | $55.23 | 2022-2025 | |
| Emd Serono, INC. | $52.97 | 2024-2025 | |
| Exelixis INC. | $52.85 | 2022-2025 | Cabometyx |
| Blueprint Medicines Corporation | $51.43 | 2021-2024 | Ayvakit |
| Adc Therapeutics America, INC. | $50.13 | 2022-2024 | |
| Astellas Pharma US INC | $46.01 | 2023-2024 | Padcev, Xospata |
| Karyopharm Therapeutics INC. | $44.99 | 2022-2023 | Xpovio |
| Syndax Pharmaceuticals, INC. | $44.92 | 2025 | |
| Puma Biotechnology, INC. | $44.90 | 2023-2024 | |
| Glaxosmithkline, LLC. | $44.89 | 2023-2024 | Ojjaara |
| Pharmacosmos Therapeutics INC. | $44.06 | 2024 | Cosela, Monoferric |
| Tersera Therapeutics LLC | $38.27 | 2023-2024 | Xermelo, Zoladex |
| Alexion Pharmaceuticals, INC. | $37.11 | 2023-2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $33.23 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $31.84 | 2019-2023 | |
| Mirati Therapeutics, INC. | $31.41 | 2023-2024 | Krazati |
| Azurity Pharmaceuticals, INC. | $31.06 | 2025 | Danziten |
| Taiho Oncology, INC. | $30.37 | 2023-2024 | |
| Springworks Therapeutics, INC. | $30.30 | 2024 | Ogsiveo |
| Genmab U.S., INC. | $29.12 | 2024 | Epkinly |
| Morphosys, US INC. | $28.04 | 2021-2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $20.81 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $19.25 | 2025 | Brukinsa |
| Geron Corporation | $16.73 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $16.15 | 2022 | |
| Immunogen, INC. | $16.10 | 2023 | Elahere |
| Aveo Pharmaceuticals, INC. | $15.82 | 2023 | Fotivda |
| Apellis Pharmaceuticals, INC. | $14.95 | 2024 | Empaveli |
| Servier Pharmaceuticals LLC | $14.12 | 2024 | |
| Myovant Sciences INC. | $12.75 | 2022 | |
| Veracyte, INC. | $12.24 | 2023 | |
| Clovis Oncology, INC. | $12.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranitha Prodduturvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.